Antares Pharma, Inc. (AIS) Welcomes Marvin Samson to Board of Directors

Mr. Samson is an expert in injectable manufacturing and delivery systems. He was formerly Group Vice President – Worldwide Injectables of Teva, previously having served as Chief Executive Officer and a member of the Board of Directors of Sicor. He was also a founder and CEO of Elkins-Sinn, Inc. and Marsam Pharmaceuticals.

Leonard S. Jacob, M.D., Ph.D., Chairman of the Board of Antares Pharma, stated, "I have been an industry colleague of Marvin Samson for many years. His broad expertise in all aspects of our business will be an important asset to us as we prepare to launch OTREXUP™ early next year. I look forward to the perspective and insight he will bring to our Company."

"I have observed the rapid growth of Antares Pharma over the past few years, and I am excited about joining the Antares Board," said Marvin Samson. "The use of drug/device combinations is very innovative, and I look forward to helping the Company as they prepare to launch OTREXUP™ followed by the Quick Shot testosterone product."

Mr. Samson was elected by shareholders at yesterday's 2013 Annual Meeting of Stockholders. In addition to his work at Elkins-Sinn and Marsam Pharmaceuticals, he is the founder and CEO of Samson Medical Technologies, a privately held company providing hospital and alternate site pharmacists with injectable drug delivery systems and programs. Mr. Samson is Chairman of the University Of Sciences Board Of Trustees. He is also Chairman of the Board of JHP Pharmaceuticals and serves on the Board of Directors of Flynn Pharma, NanoPass Technologies Ltd and Emcure Pharmaceuticals Ltd. Additionally, Mr. Samson served as Chairman of the Board and CEO of Qualitest Pharmaceuticals prior to its purchase by Endo Pharmaceuticals in late 2010 and as the Chairman of the Generic Pharmaceutical Industry Association from 1997 to 2000. Mr. Samson is the holder of five U.S. patents pertaining to pharmaceutical manufacturing. Mr. Samson graduated from Temple University with a B.S. in Chemistry.

Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, "We are very fortunate to have someone of Marvin's background and experience join the Board of Directors of Antares. His extensive commercial expertise in injectable manufacturing and delivery systems will be invaluable as we launch new products and add to an already exciting pipeline."

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma's partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company's corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are indicated by the words "may," "will," "plans," "intends," "believes," "expects," "anticipates," "potential," "could," "would," "should," and similar expressions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others, changes in revenue growth and difficulties or delays in the initiation, progress, or completion of product development. In addition, the OTREXUP™ and Quick Shot testosterone products referred to in this press release have not yet been approved by the FDA, and the commercialization of OTREXUP™ and Quick Shot testosterone are dependent on the Company receiving FDA approval of these products. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Contacts